At a glance
ClinicalIndex Comparison RecordN/ACompleted· 34 enrolled
Drug / intervention
18F-DCFPyL +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma
In Brief
A clinical study evaluating 18F-DCFPyL and PET/CT for Renal Cell Carcinoma and Kidney Cancer. Completed, enrolled 34 participants across 1 site.
Detailed Summary
In this study the investigators aim to evaluate diagnostic utility of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL PET/CT in patients with renal cell carcinoma (RCC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma, Kidney Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartOct 2015
First PostedFeb 2016
Primary CompletionApr 2019
TodayJul 2026
First PostedFeb 22, 2016
Enrollment StartOct 1, 2015
Primary CompletionApr 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 10.4 years ago
Interventions
18F-DCFPyLdrug
PET/CTprocedure
Positron Emission Tomography - Computed Tomography (PET/CT)